Drug Trial Radar · NCT03070392
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
378
Actual
Start
Oct 16, 2017
Primary completion
Oct 13, 2020
Study completion Sep 17, 2025
Sponsor
- Lead sponsor
- Immunocore LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 3, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
Conditions
- Uveal Melanoma
Interventions
IMCgp100Biological
IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity
DacarbazineDrug
Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity
IpilimumabBiological
Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments
PembrolizumabBiological
Pembrolizumab is to be administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months.
Locations
57 sites in 14 countries. Site status is shown where the registry gives one.
UCLA Medical Center
Los Angeles, California
The Angeles Clinic and Research Institute
Los Angeles, California
Byers Eye Institute, Stanford University
Palo Alto, California
California Pacific Medical Center
San Francisco, California
University of Colorado
Aurora, Colorado
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
The University of Chicago Medicine
Chicago, Illinois
University of Iowa
Iowa City, Iowa
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Roswell Park Cancer Institute
Buffalo, New York
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University Health System
Durham, North Carolina
The Ohio State University
Columbus, Ohio
University of Oklahoma
Oklahoma City, Oklahoma
Portland Providence Medical Center
Portland, Oregon
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Houston Methodist Cancer Center
Houston, Texas
Saint Vincents Hospital
Darlinghurst, New South Wales, Australia
Central Adelaide Local Health Network, Royal Adelaide Hospital Cancer Center
Adelaide, South Australia, Australia
Peter MacCallum Cancer Center
Melbourne, Victoria, Australia
Institut Roi Albert II Cliniques Universitaires St-Luc
Brussels, Belgium
Universite Catholique de Louvain Centre du Cancer, Medical Oncology
Brussels, Belgium
Princess Margaret Cancer Centre
Toronto, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
Centre Atoine Lacassagne
Nice, France
Institut Curie
Paris, France
Charite - Campus Benjamin Franklin
Berlin, Germany
Universitätsklinikum Carl Gustav Carus
Dresden, Germany
University Hospital Essen
Essen, Germany
University of Hamburg
Hamburg, Germany
Nationales Centrum für Tumorerkrankungen
Heidelberg, Germany
Klinik und Poliklinik für Dermatologie und Allergologie
Munich, Germany
Universitaetsklinikum Koeln Dermatologie und Venerologie
Cologne, North Rhine-Westphalia, Germany
Fondazione ICCRS
Milan, Italy
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.